Cybin, Inc. (TSE:CYBN) has released an update.
Cybin Inc. has launched a Phase 2 study for CYB004, their novel DMT-based treatment aimed at Generalized Anxiety Disorder, expecting to disrupt negative thought patterns with a short, 90-minute treatment duration. The study follows FDA clearance and builds on positive preliminary results from earlier trials, with topline safety and efficacy data anticipated by the end of 2024. This development is part of Cybin’s broader commitment to advancing mental healthcare with two leading clinical programs making significant strides.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
